{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:08:32Z","timestamp":1760609312444},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,10,15]]},"DOI":"10.2169\/internalmedicine.4445-20","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T22:08:42Z","timestamp":1602713322000},"page":"2457-2464","source":"Crossref","is-referenced-by-count":5,"title":["Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study"],"prefix":"10.2169","volume":"59","author":[{"given":"Kazuo","family":"Notsumata","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Fukui Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimoto","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukui Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukui Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikatsu","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukui Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruyuki","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukui Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Sanada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukui Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukui Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisyu","family":"Toya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukui Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy:diagnosis and management. J Gastroenterol Hepatol 25: 864-871, 2010."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Wursthorn K, Wedemeyer H, Manns MP. Managing HBV in patients with impaired immunity. Gut 59: 1430-1445, 2010.","DOI":"10.1136\/gut.2009.195834"},{"key":"3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","volume":"100","author":"AS Lok","year":"1991","unstructured":"3. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182-188, 1991.","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"4","unstructured":"4. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation un cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299-307, 2000."},{"key":"5","unstructured":"5. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 16: 13-18, 1992."},{"key":"6","unstructured":"6. Carrol MB, Forgione MA. Use of tumor necrosis factor alfa inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 29: 1021-1029, 2010."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Urata Y, Uesato R, Tanaka D, et al. Prevalance of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21: 16-23, 2011.","DOI":"10.3109\/s10165-010-0337-z"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Aqqeletopoulou I, Konstantakis C, Manolakopoulos S, et al. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol 23: 4317-4323, 2017.","DOI":"10.3748\/wjg.v23.i24.4317"},{"key":"9","unstructured":"9. JSH Guidelines for the Management of Hepatitis B. Committee for Hepatitis Management Guidelines and the Japan Society. 2019."},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Notsumata K, Kumai T, Ueda T, et al. Automated risk management of HBV reactivation by encoding patients'medical records. Kanzo 55: 91-99, 2014 (in Japanese, Abstract in English).","DOI":"10.2957\/kanzo.55.91"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90: 13-23, 2009.","DOI":"10.1007\/s12185-009-0359-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kusumoto S, Tanaka Y, Ueda R, et al. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 46: 9-16, 2011.","DOI":"10.1007\/s00535-010-0331-4"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Hsu C, Tsaou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 59: 2092-2100, 2014.","DOI":"10.1002\/hep.26718"},{"key":"14","unstructured":"14. Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis 61: 719-725, 2015."},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Chou CK, Wang LH, Lin HM, et al. Glucocortiroid stimulates hepatitis B viral gene expression in cultured human hepatoma cell. Hepatology 16: 13-18, 1992.","DOI":"10.1002\/hep.1840160104"},{"key":"16","unstructured":"16. Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA 310: 1664, 2013."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Kusumoto S, Arcaini I, Hong X, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 133: 137-146, 2019.","DOI":"10.1182\/blood-2018-04-848044"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nakano N, Kusumoto S, Tanaka Y, et al. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the ant-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res 44: 354-357, 2014.","DOI":"10.1111\/hepr.12117"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 74: 254-258, 2005.","DOI":"10.1111\/j.1600-0609.2004.00375.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Law MF, Ho R, Cheung CK, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol 22: 6484-6500, 2016.","DOI":"10.3748\/wjg.v22.i28.6484"},{"key":"21","unstructured":"21. Noguchi Y, Tsurushima M, Tamura Y, et al. A case of hepatitis B virus reac ivation with prior resolved hepatitis B infection during bevacizumab plus FORFIRI treatment. Gan To Kagaku Ryoho 40: 1561-1563, 2013 (in Japanese, Abstract in English)."},{"key":"22","unstructured":"22. Shinkai N, Kusumoto S, Murakami S, et al. Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay. Liver Int."},{"key":"23","unstructured":"23. Fukuda W, Hanyu T, Katayama M, et al. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther 21: 255, 2019."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Mochida S, Nakao M, Nakayama N, et al. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. J Gastroenterol 51: 999-1010, 2016.","DOI":"10.1007\/s00535-016-1168-2"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/20\/59_4445-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T03:44:24Z","timestamp":1602906264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/20\/59_4445-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":24,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4445-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}